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Objectives: Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial
pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications. We evaluated the bronchopul-
monary pharmacokinetic/pharmacodynamic profile of this 3 g ceftolozane/tazobactam regimen in ventilated
pneumonia patients.
Methods: This was an open-label, multicentre, Phase 1 trial (clinicaltrials.gov: NCT02387372). Mechanically ven-
tilated patients with proven/suspected pneumonia received four to six doses of 3 g of ceftolozane/tazobactam
(adjusted for renal function) q8h. Serial plasma samples were collected after the first and last doses. One
bronchoalveolar lavage sample per patient was collected at 1, 2, 4, 6 or 8 h after the last dose and epithelial
lining fluid (ELF) drug concentrations were determined. Pharmacokinetic parameters were estimated by non-
compartmental analysis and pharmacodynamic analyses were conducted to graphically evaluate achievement
of target exposures (plasma and ELF ceftolozane concentrations >4 mg/L and tazobactam concentrations
>1 mg/L; target in plasma:30% and20% of the dosing interval, respectively).
Results: Twenty-six patients received four to six doses of study drug; 22 were included in the ELF analyses.
Ceftolozane and tazobactam Tmax (6 and 2 h, respectively) were delayed in ELF compared with plasma (1 h).
Lung penetration, expressed as the ratio of mean drug exposure (AUC) in ELF to plasma, was 50% (ceftolozane)
and 62% (tazobactam). Mean ceftolozane and tazobactam ELF concentrations remained >4 mg/L and >1 mg/L,
respectively, for 100% of the dosing interval. There were no deaths or adverse event-related study
discontinuations.
Conclusions: In ventilated pneumonia patients, 3 g of ceftolozane/tazobactam q8h yielded ELF exposures
considered adequate to cover ceftolozane/tazobactam-susceptible respiratory pathogens.
Introduction
Critically ill patients with nosocomial pneumonia are challenging
to treat: they exhibit notable alterations in antimicrobial pharma-
cokinetics (PK) and often have multiorgan dysfunction, immune
system dysfunction and/or infections caused by resistant patho-
gens; these factors all contribute to poor clinical outcomes.1–4
Nosocomial pneumonia, in particular ventilator-associated bacter-
ial pneumonia (VABP) and ventilated hospital-acquired bacterial
pneumonia (vHABP), is associated with high mortality, which
reaches >40% in VABP caused by Pseudomonas aeruginosa and in
vHABP.5–7 Since patients with pneumonia who require mechanical
ventilation are at high risk of mortality and other adverse
outcomes, they must promptly receive appropriate antibacterial
therapy.8–13 P. aeruginosa, including MDR strains, and
Enterobacteriaceae (new taxonomy: Enterobacterales), including
ESBL-producing strains, are the most common Gram-negative
pathogens implicated in this setting.14 Given the prevalence of drug-
resistant Gram-negative pathogens in nosocomial pneumonia, new
safe and broadly effective treatment options that can reach suffi-
cient concentrations at the target site are urgently needed.4
Ceftolozane/tazobactam is a cephalosporin/b-lactamase inhibi-
tor combination consisting of ceftolozane, a potent antipseudomo-
nal (including most MDR strains) cephalosporin, and tazobactam,
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an established b-lactamase inhibitor expanding ceftolozane’s ac-
tivity against Enterobacteriaceae producing certain ESBLs.15–19
Both ceftolozane and tazobactam have dose-proportional, linear,
independent PK. Both are renally eliminated, ceftolozane almost
exclusively as unchanged drug and tazobactam partially (20%)
as the pharmacologically inactive metabolite tazobactam M1;
with normal renal function or mild renal impairment, elimination
half-lives in patients (derived from population PK modelling)
are approximately 3–4 h and 2–3 h, respectively.20 The lack of
drug–drug interaction between both agents probably occurs be-
cause ceftolozane is almost exclusively eliminated by passive
glomerular filtration, so it does not interfere with the active tubu-
lar secretion of tazobactam.16,20,21 For treatment of ventilated
nosocomial pneumonia, ceftolozane/tazobactam is approved at
a dose of 3 g (2 g of ceftolozane and 1 g of tazobactam) q8h,
adjusted based on renal function, which is double the dose
recommended for other indications.20 This higher dose was
projected to achieve 98% PTA in pulmonary epithelial lining fluid
(ELF) against pathogens with a ceftolozane/tazobactam MIC of
8 mg/L,22 based on prospective data showing good intrapulmo-
nary penetration in healthy volunteers.23 In the recently com-
pleted ASPECT-NP Phase 3 trial, the 3 g ceftolozane/tazobactam
regimen was non-inferior to meropenem for treatment of HABP/
VABP in both primary and key secondary endpoints.24
Since bronchopulmonary disposition in critically ill patients
could be different compared with healthy volunteers,4,25–27 it is
important to evaluate the exposure profile of ceftolozane/tazobac-
tam specifically in this high-risk population.28,29 To further evalu-
ate the clinical utility of the 3 g dose of ceftolozane/tazobactam in
nosocomial pneumonia, we conducted a clinical trial to assess
the bronchopulmonary penetration of both ceftolozane and tazo-
bactam in mechanically ventilated patients with pneumonia.
Patients and methods
Study design
Protocol MK-7625A-007 was a prospective, open-label, multicentre, Phase 1
study characterizing PK, safety and tolerability of ceftolozane/tazobactam
in critically ill adults, with two patient cohorts (clinicaltrials.gov:
NCT02387372). Herein, we report results from the first cohort, which com-
prised mechanically ventilated patients concurrently receiving standard-of-
care antibacterial therapy for proven or suspected pneumonia. Patients
were enrolled at 10 study sites [mostly medical or surgical ICUs; Table S1
(available as Supplementary data at JAC Online)] in Belgium, Spain and
the USA between May 2015 and June 2017. The full study protocol is also
available as Supplementary data at JACOnline.
Ethics
The study was conducted in accordance with principles of Good Clinical
Practice and was approved by the appropriate regulatory agencies. Ethics
approval was obtained from each participating institution’s appropriate
institutional review board (see Table S1 for the specific independent ethics
committees). Each patient, or a legal representative, provided written
informed consent and was able to withdraw from the study at any time.
Patients
Patients were 18 years old with proven/suspected pneumonia who
were hospitalized in the ICU while receiving mechanical ventilation for
24 h before enrolment and were expected to continue ventilation for
8 h following the final study dose. Proven/suspected pneumonia was
defined as the presence of at least one of the following: fever (body tempera-
ture >38.5C), hypothermia (body temperature <35.0C), elevated WBC
count 12 000 cells/mm3 or chest radiograph showing pneumonia charac-
teristics. Patients had to be receiving antibacterial therapy for pneumonia at
enrolment and likely to require continued antibacterial therapy while in the
study. Patients were excluded for: baseline haemoglobin levels <7 g/dL;
end-stage renal disease, defined as CLCR <15 mL/min (calculated using the
Cockcroft–Gault equation based on actual body weight) and/or requirement
for continuous renal replacement therapy or haemodialysis; prior (24 h
before first study dose) or concomitant receipt of piperacillin/tazobactam,
non-study ceftolozane/tazobactam or probenecid; or conditions that
may interfere with PK assessment or interpretation (e.g. cystic fibrosis, acute
exacerbation of chronic bronchitis or obstructive airway disease, chronic
severe respiratory disease, active pulmonary TB or lung transplant).
Study drug
Eligible patients received four to six doses of ceftolozane/tazobactam q8h,
administered as 60 min IV infusions. Dosage was adjusted for renal
function: 3 g of ceftolozane/tazobactam (2 g of ceftolozane and 1 g of tazo-
bactam) for patients with CLCR >50 mL/min; 1.5 g (1 g of ceftolozane and
500 mg of tazobactam) for patients with CLCR between 30 and 50 mL/min;
and 750 mg (500 mg of ceftolozane and 250 mg tazobactam) for patients
with a CLCR between 15 and 29 mL/min. CLCR was calculated once daily, at
a consistent time, while receiving study drug. Patients receiving the lowest
ceftolozane/tazobactam regimen needed to receive six doses to achieve
steady-state plasma concentrations, while for all other patients the
number of doses was at the investigator’s discretion to facilitate timing of
bronchoalveolar lavage (BAL).
Plasma and ELF sample collection
Blood samples for plasma concentration determination of ceftolozane and
tazobactam were collected at 0 (pre-dose), 1, 2, 4, 6 and 8 h after start of in-
fusion during the first and final (i.e. fourth, fifth or sixth) doses of ceftolo-
zane/tazobactam. At least 5.0 mL of blood was collected per timepoint
using a sodium heparin vacutainer tube, which was then mixed by inverting
five times and kept on ice after collection. Blood samples were centrifuged
at approximately 4C within 30 min of collection at 3000 rpm (approxi-
mately 2056g force) for 15–20 min to achieve a clear plasma layer over the
red cells. Plasma samples were subsequently aliquotted into pre-chilled
polypropylene cryotubes and immediately frozen and stored at #80±10C
in an upright position.
All patients were randomly assigned to undergo one bronchoscopy
and BAL (of the lung segment identified as containing the pneumonia) at 1
(±30 min), 2 (±30 min), 4 (±30 min), 6 (±30 min) or 8 (±30 min) h after
start of the final study drug infusion (n= 5 per timepoint). Each BAL
utilized four aliquots of sterile 0.9% saline: the initial aliquot (50 mL) was
discarded and the subsequent aliquots (20 mL each) were stored on ice,
pooled and centrifuged for 5 min at 400g force at approximately 4C.
Immediately after centrifugation, the supernatant was aliquotted into
three 15 mL amber-coloured specimen bottles, which were frozen at
#80±10C within 17 h of sample collection and then shipped to a central
laboratory.
Safety and tolerability were assessed throughout the study by examin-
ing adverse events (AEs), changes in clinical laboratory test results
and changes in vital signs. AEs were collected throughout the study until
24–48 h after the last dose of study drug.
Drug concentration determination
Concentrations of ceftolozane and tazobactam in plasma and BAL fluid
were determined at MicroConstants (San Diego, CA, USA), using a validated
HPLC–tandem MS method described in detail previously.23,30 For plasma,
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the analytical ranges were 0.250 to 150 mg/L (ceftolozane) and 0.100 to
60.0 mg/L (tazobactam). For BAL fluid, the analytical ranges were 1.00 to
1000 ng/mL (ceftolozane) and 1.00 to 250 ng/mL (tazobactam), with ac-
curacy of 95.5% (ceftolozane) and 94.5% (tazobactam) and precision
ranging from 6.27% to 7.78% and 5.37% to 10.1%, respectively. To account
for dilution from the saline instillations during BAL, drug concentrations in
ELF were estimated by correcting the respective BAL concentrations using
the urea dilution method.31 Urea concentrations were also determined at
MicroConstants, using an unmodified version of the colorimetric BioChain
Urea Assay Kit (BioChain Institute Inc., Newark, CA, USA). This validated urea
assay had an analytical range of 2.50 to 50.0 mg/dL (plasma) and 0.150 to
2.50 mg/dL (BAL fluid) and for BAL fluid had an accuracy ranging from
95.00% to 98.50% and precision ranging from 7.54% to 10.9%. For BAL
samples without detectable urea concentrations using this assay, a high-
sensitivity assay with an analytical range of 0.0500 to 1.00 mg/dL was subse-
quently used; the high-sensitivity assay was also based on the BioChain Urea
Assay Kit, but used 300lL of sample and 400lL of chromogenic solution (in-
stead of 75lL and 200lL, respectively, for the unmodified assay). Urea con-
centrations were assessed from the same samples as drug concentrations.
PK and pharmacodynamic (PD) analyses
PK parameters were estimated by non-compartmental analyses (NCAs)
using Phoenix WinNonlin version 6.3 (Certara, Princeton, NJ, USA). The AUC
was calculated using the linear up/log down method. Plasma PK parame-
ters were calculated using actual sampling times. Individual ELF concentra-
tions measured at each timepoint (i.e. 1, 2, 4, 6 and 8 h post-dose) were
averaged (as geometric means) across all patients with data from that par-
ticular timepoint; these pooled, mean concentrations were used to compile
one ELF concentration–time profile from which the ELF PK parameter values
were estimated using NCA. When conducting this NCA, average 0 h pre-
dose concentrations were assumed to be the same as average 8 h post-
dose concentrations. Since in ELF only a single PK profile was created for
ceftolozane and tazobactam, statistical measures of variability could not
be calculated. All plasma drug concentrations are reported as unbound
plasma concentrations, estimated assuming 21% protein binding for cefto-
lozane and 30% for tazobactam.20 In ELF, 0% protein binding was assumed
for both ceftolozane and tazobactam, and all ELF drug concentration are
reported as total ELF concentrations. Since the dose was adjusted based on
CLCR, drug exposure was expected to be similar across dosing regimens and
individual ceftolozane and tazobactam PK results were pooled across all
dose levels for analysis. Ceftolozane and tazobactam lung penetration was
calculated as the ratio of the mean AUC0–8 in ELF to the mean unbound
AUC0–8 in plasma.
We also evaluated graphically how individual plasma concentration–
time profiles (for both first and last doses) and the mean ELF concentra-
tion–time profiles (for last dose) related to specific target concentrations.
The established PK/PD target for ceftolozane, based on previously
published work, is the free plasma ceftolozane concentration remaining at
>4 mg/L (the CLSI susceptibility breakpoint for P. aeruginosa) for 30%
of the 8 h dosing interval; as a sensitivity analysis we also assessed a PK/
PD target of >8 mg/L (the CLSI intermediate susceptibility breakpoint for
P. aeruginosa).32,33 The established PK/PD target for tazobactam is the
free tazobactam plasma concentration remaining at >1 mg/L (threshold
concentration needed to effectively neutralize susceptible bacterial b-lac-
tamases) for 20% of the dosing interval.34 For ELF, the duration that
absolute ceftolozane and tazobactam exposures remained above these
respective concentration thresholds was explored.
Results
Patients
Of the 27 patients enrolled, 26 (96%) received ceftolozane/tazo-
bactam; 1 patient was extubated prior to treatment assignment
and was discontinued from the study without receiving study
drug. In these 26 patients, CLCR ranged from 37.7 to 355.6 mL/min,
including 8 patients (30.8%) with augmented renal clearance
(defined as CLCR values >150 mL/min). Twenty-one patients
received 3 g of ceftolozane/tazobactam, four received 1.5 g of
ceftolozane/tazobactam (dosing of one patient was adjusted
from 1.5 to 3 g for the fourth and fifth doses because of increased
CLCR post-baseline) and one received 750 mg of ceftolozane/
tazobactam.
Among the 26 patients who received ceftolozane/tazobactam,
25 provided data for plasma PK analyses and 22 provided data for
BAL PK analyses. One patient was excluded from the plasma PK
analyses due to having received an incorrectly adjusted ceftolo-
zane/tazobactam dose (i.e. 1.5 g of ceftolozane/tazobactam
despite having had a CLCR >50 mL/min). This patient was also
excluded from the BAL PK analyses, along with three other
patients who either had no BAL performed (one was extubated
prior to the last dose and another was deemed too clinically
unstable to undergo the procedure) or had no urea detected in
BAL fluid (one patient). Baseline demographic and clinical charac-
teristics of the 22 patients comprising the ELF PK population are
summarized in Table 1.
PK and PD analyses
Plasma and ELF PK parameter estimates are presented in Table 2
as geometric means. Plasma accumulation from the first to the
last dose was 1.6- and 1.2-fold for ceftolozane and tazobactam
AUC0–8, respectively. The median ceftolozane and tazobactam
Tmax in plasma were 1 h for both the first and last doses (Table 2
and Figure 1). Ceftolozane and tazobactam Tmax in ELF after the
last dose were 6 and 2 h, respectively (Table 2 and Figure 1). Lung
penetration was approximately 50% for ceftolozane and 62% for
tazobactam.
After the first and last doses, all patients had drug exposures in
plasma that were above the PK/PD targets for both ceftolozane
and tazobactam. Figure 2 illustrates that plasma exposures above
these targets were rapidly achieved for both ceftolozane and tazo-
bactam in all patients and sustained for the duration of the entire
dosing interval in most patients. Following the last dose, the geo-
metric mean unbound plasma ceftolozane concentration
remained >4 mg/L for approximately 100% (range: 98%–100%)
and >8 mg/L for approximately 96% (range: 64%–100%) of the
dosing interval and the geometric mean unbound tazobactam
plasma concentration remained >1 mg/L for approximately 82%
(range: 35%–100%) of the dosing interval (Table S2). In patients
with augmented renal clearance, geometric mean total ceftolo-
zane concentrations in plasma remained >4 mg/L for 99.7% and
mean total tazobactam concentrations >1 mg/L for 75.5% of the
dosing interval following the last dose. In ELF, arithmetic and geo-
metric mean total ceftolozane and tazobactam concentrations
remained >4 mg/L (and also >8 mg/L in a sensitivity analysis) and
>1 mg/L, respectively, for 100% of the dosing interval following the
last dose (Figure S1 and Table S2); this was also the case for
patients with augmented renal clearance.
Figure S2 shows individual drug concentrations for patients
in the ELF PK population who received renally adjusted doses of
ceftolozane/tazobactam (i.e. <3 g q8h) compared with average
concentrations in patients with normal renal function (who
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received 3 g q8h). Individual ceftolozane and tazobactam concen-
trations in these renally impaired patients generally fell within the
5th and 95th percentiles of the median concentrations observed in
patients with normal renal function, suggesting that the dose
adjustments made according to renal function were adequate to
allow pooling of the data. The appropriateness of pooling these
data was also confirmed by the individual plasma concentration–
time profiles, which were similar between both groups of patients.
Safety
There were 43 treatment-emergent AEs experienced by 16 of the
26 patients (61.5%) who received ceftolozane/tazobactam; all of
these AEs were mild to moderate in severity (Table S3). There were
no deaths or serious AEs. No patients discontinued the study due
to an AE. The most frequent treatment-emergent AEs, and the
only ones reported in at least two patients, were anaemia and
diarrhoea (Table S4). Two patients had treatment-related AEs:
moderate thrombocytopenia (n= 1) and moderate diarrhoea
(n= 1), both of which resolved by the final study visit.
Discussion
In patients with nosocomial pneumonia, drug exposure in the
lungs is recognized as a crucial factor for determining dosing regi-
mens likely to result in good clinical outcomes.28 Ceftolozane/tazo-
bactam is a cephalosporin/b-lactamase inhibitor combination
recently approved for treating nosocomial pneumonia using a 3 g
q8h regimen, which is double the dose recommended for other
indications.20 Since critically ill patients often have differences in
drug PK and tissue distribution compared with healthy individu-
als,26–29,35 it is important to evaluate bronchopulmonary concen-
trations specifically in this group of patients.28,36 The purpose of
our unique and rigorously conducted clinical trial was to assess
whether the 3 g dose would provide adequate lung penetration to
achieve ceftolozane and tazobactam concentrations above rele-
vant target thresholds, for which an NCA was sufficient. The data
from this study will be combined with a larger set of sparse PK data
from the recently completed large, randomized, controlled,
ASPECT-NP24 trial using a population PK approach and subsequent
modelling and target attainment simulations.36 Of note, in
ASPECT-NP, which was conducted exclusively in patients with ven-
tilated nosocomial pneumonia, the 3 g dose of ceftolozane/tazo-
bactam was shown to be efficacious for the treatment of HABP/
VABP.
Our results demonstrated that lung penetration for both cefto-
lozane and tazobactam (50% and 62%, respectively, based on
mean PK profiles) was similar between the critically ill, mechanical-
ly ventilated patients with pneumonia enrolled in our trial and the
healthy volunteers previously studied (61% and 63%, respectively,
assuming 21% and 30% plasma protein binding, respectively).23
Of note, steady-state plasma AUC, Cmax and terminal half-life for
both ceftolozane and tazobactam observed in our study popula-
tion of ventilated, critically ill pneumonia patients were very similar
to the respective population PK-derived values from the ASPECT-
NP clinical trial in mechanically ventilated patients with HABP/
VABP and CLCR >50 mL/min.
20 Importantly, mean ceftolozane and
tazobactam ELF concentrations in this pharmacologically com-
plex, high-risk population remained above 8 mg/L and 1 mg/L,
respectively, for 100% of the dosing interval. Our results also dem-
onstrated that the 3 g q8h ceftolozane/tazobactam regimen
achieved established PK/PD targets [i.e. ceftolozane plasma con-
centrations remaining above 4 mg/L (and also above 8 mg/L) for at
least 30% and tazobactam concentrations remaining above 1 mg/L
for at least 20% of the dosing interval].32,34 These thresholds were
also met in patients with augmented renal clearance. (Previously
published population PK analyses37,38 and a clinical trial in HABP/
VABP24 also support the notion that the presence of augmented
renal clearance does not necessitate ceftolozane/tazobactam dose
adjustments.) Furthermore, the 3 g dose was generally well toler-
ated, just as in other clinical trials assessing this higher regi-
men,21,24,30,39 with no AEs reported as serious, severe or resulting in
treatment discontinuation.
Interpatient variability in plasma PK was higher in these critical-
ly ill patients, which is not surprising given the generally more
complex physiological variation in this population.26–29 Drug distri-
bution, as a function of time to reach maximum drug concentra-
tion in ELF, was delayed in critically ill pneumonia patients versus
healthy volunteers,23 but overall ELF drug exposures per dosing
interval were similar in both study populations. These results
Table 1. Baseline demographics and clinical characteristics of patients
included in the ELF PK analysis (N= 22)
Baseline demographics
age (years), mean±SD (range) 63.0±16.3 (21–88)
male, n (%) 15 (68)
race, n (%)
white 16 (73)
black 6 (27)
weight (kg), mean±SD (range) 89.6±25.3 (46.0–142.0)
BMI (kg/m2), mean±SD (range) 30.6±9.3 (13.8–55.5)
CLCR (mL/min), mean±SD (range) 121.5±76.6 (23.7–355.6)
Reason for ICU admission, n (%)
cardiac disordersa 5 (23)
gastrointestinal disordersb 1 (5)
injuriesc 4 (18)
infectionsd 2 (9)
nervous system disorderse 3 (14)
psychiatric disordersf 1 (5)
respiratory, thoracic and
mediastinal disordersg
6 (27)
Pneumonia diagnosis, n (%)
confirmed 20 (91)
suspected 2 (9)
aCardiac arrest (n= 4) and cardiopulmonary arrest.
bGastrointestinal haemorrhage.
cRoad traffic accident, gunshot wound, traumatic brain injury and
subdural haematoma.
dSevere sepsis (secondary to community-acquired pneumonia) and
sepsis (secondary to empyema).
eCerebral artery stroke, intraparenchymal haemorrhage and neurologic-
al deterioration.
fAltered mental status.
gRespiratory failure (n= 2), aspiration pneumonia, dyspnoea, haemo-
thorax and massive haemoptysis.
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suggest that certain pathophysiological factors (e.g. capillary leak-
age or fluid loading) in patients with pneumonia may delay cefto-
lozane/tazobactam distribution into ELF; however, the overall
effect on ceftolozane/tazobactam lung penetration and, most im-
portant, on the critical PK/PD parameters of time above ceftolo-
zane and tazobactam target concentrations, appears not to be
clinically relevant. Taken as a whole, these bronchopulmonary dis-
position data suggest that the 3 g dose regimen provides adequate
drug exposure in ventilated, critically ill patients with pneumonia.
Of note, volume of distribution is often much greater in critically ill
patients with infections than in healthy volunteers and non-
critically ill patients.27 This was the case with our study participants
(plasma Vss 29 L) compared with healthy volunteers who also
received multiple doses of 3 g of ceftolozane/tazobactam q8h
(plasma Vss18 L).30
Although ELF concentration data have previously been reported
for various antibacterial agents, including other novel b-lactam/
b-lactamase inhibitor combinations, most such assessments of
antibacterial lung penetration were only conducted in healthy
volunteers.23,40–43 In our study, the rigour of intensive plasma
PK sampling and structured timing of plasma and BAL sample
collection were similar to methods employed in healthy volunteer
studies, but were applied to a study population intended to be
representative of real-world patients encountered in clinical prac-
tice (including those with augmented renal clearance or renal dys-
function) and similar to the study population of a Phase 3 trial that
evaluated ceftolozane/tazobactam for nosocomial pneumonia.
Therefore, patients with a range of renal function were eligible, as
were patients receiving concomitant medications not expected to
interfere with the PK of ceftolozane or tazobactam. Furthermore,
patients were enrolled worldwide at multiple sites and a standar-
dized BAL sampling procedure was outlined to minimize intersite
sampling variability.
Nonetheless, the high variability we observed in the plasma
and ELF PK data (particularly high for plasma half-life) was antici-
pated, due to the physiological complexity of our study population
compared with healthy volunteers. Since ceftolozane/tazobactam
is mainly renally eliminated, and CLCR is therefore the primary vari-
able influencing and predicting exposure, this observed plasma
variability was probably due to differences in patients’ baseline
renal function (as evident by the wide range of baseline CLCR lev-
els). A comparison of drug concentrations in patients with normal
versus those with impaired renal function showed that it was ap-
propriate to pool all patients regardless of whether or not they
underwent CLCR-based dose adjustments, based on the similarities
between the respective ceftolozane and tazobactam exposures.
This approach is supported by previous studies that demonstrated
similar drug exposures across the approved ceftolozane/tazobac-
tam dose categories.38,44,45 CLCR, calculated once daily, was a suit-
able marker for renal function because it reflects exactly how
ceftolozane/tazobactam should be used in clinical practice.20 (Of
note, there is evidence that renal function-based dose adjust-
ments made during the first 48–72 h of antibacterial treatment
could result in underdosing, because more than half of all patients
with renal impairment at treatment initiation appear to improve
renal function within that time frame.46 This further highlights the
importance of daily CLCR estimation during ceftolozane/tazobac-
tam treatment20—paying close attention to likely renal function
improvements in patients with acute kidney injury and CLCR-based
dose adjustments will allow for rapid escalation to the standard
dosing regimen once appropriate.) Additionally, all but one patient
had stable renal function from baseline throughout the study. High
interpatient variability was also noted in ELF concentrations at vari-
ous timepoints, with a concentration difference greater than10-
fold at some timepoints (e.g. at 4 h post-dose). Given that only one
BAL sample for evaluation of ceftolozane/tazobactam ELF concen-
trations could be collected per patient, a composite ELF concentra-
tion–time profile was used. Current study designs for ELF sampling
have limitations and can lead to overestimation of variability in ELF
Table 2. PK parameters for ceftolozane and tazobactam, presented as
geometric mean (geometric coefficient of variation %) unless otherwise
noted, in plasma and ELF among ventilated, critically ill patients with
pneumonia who received 3 g of ceftolozane/tazobactam (dose-adjusted
for renal impairment) q8h for four to six doses
PK parameter
Plasma
ELFd, last
dose (N= 22)
first dose
(N= 25)
last dose
(N= 24)a
Ceftolozane
AUC0–8 (mgh/L) 248 (40.6)b 392 (57.8)c 154
Cmax (mg/L) 73.0 (42.3) 101 (45.9) 27.4
Tmax (h), median
(range)
1.00 (0.88–2.00) 1.00 (0.92–2.17) 6e
Clast (mg/L) 14.0 (70.7) 23.8 (100.0) 7.54
Vss (L) 27.5 (29.9)
b 29.4 (45.5)c NA
CL (L/h) 4.90 (64.1)b 4.52 (67.7)c NA
t1=2 (h) 4.15 (56.1)
b 4.86 (61.5)c NA
Tazobactam
AUC0–8 (mgh/L) 51.3 (49.4) 63.0 (64.8)c 27.5
Cmax (mg/L) 22.6 (41.1) 26.2 (50.1)
c 5.37
Tmax (h), median
(range)
1.00 (0.88–1.12) 1.00 (0.92–2.17) 2e
Clast (mg/L) 1.14 (147.4) 1.49 (169.9) 1.11
Vss (L) 39.9 (28.9) 40.4 (38.8)
c NA
CL (L/h) 15.0 (68.5) 14.1 (75.6)c NA
t1=2 (h) 2.15 (56.4) 2.33 (49.7)
c NA
AUC0–8, area under the concentration–time curve from time 0 to 8 h
(i.e. the dosing interval); Cmax, maximum observed concentration; Tmax,
time to maximum observed concentration; Clast, last quantifiable
concentration; Vss, volume of distribution at steady-state; CL, clearance;
t1=2, terminal half-life; NA, not available.
aOne patient was extubated prior to the final plasma PK sampling.
bData available from 24 patients: 1 patient had the last timepoint col-
lected after the next dose, so PK data for the last timepoint were
excluded.
cData available from 23 patients: 1 patient received a commercial prod-
uct instead of the study drug at 6 h, so PK data for the last timepoint
were excluded.
dELF data were pooled at each timepoint to allow PK parameters to be
generated. Since a single, pooled PK profile was determined in ELF, stat-
istical measures of variability cannot be calculated for any ceftolozane
and tazobactam PK parameters in ELF.
eThis Tmax corresponds to the time when the pooled ELF concentration-
time profile, calculated based on geometric mean values at each time-
point, reached the maximum concentration.
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Figure 2. Individual unbound plasma concentration–time profiles for first (n= 25) and last (n= 24) doses, with target concentrations shown as hori-
zontal lines, among patients included in the plasma PK analyses, for (a) ceftolozane first dose, (b) ceftolozane last dose, (c) tazobactam first dose
and (d) tazobactam last dose.
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Figure 1. Arithmetic mean (±SD) total concentration–time profiles in plasma [first dose (n= 25 patients) and last dose (n= 24 patients)] and ELF (last
dose; n= 22 patients) for (a) ceftolozane and (b) tazobactam. Note: curves are slightly offset around each timepoint in order to achieve separation of
error bars.
Caro et al.
6 of 8
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/doi/10.1093/jac/dkaa049/5811380 by G
hent U
niversity user on 22 April 2020
concentration data.36 It was therefore not possible to determine
whether the high interpatient variability observed at specific time-
points was reflective of high interpatient variability in PK parame-
ters (e.g. AUC or half-life) or patient characteristics (e.g. disease
state, age or renal function). The ELF variability we observed in crit-
ically ill patients appeared to be greater than that previously
reported from healthy volunteers.23 Of note, results from a porcine
pneumonia model suggest that a single BAL sampling timepoint
is sufficient to predict the median penetration and variability
for ceftolozane.47 Therefore, although significant interpatient vari-
ability was observed in our study, it is reasonable to use the mean
profile from pooled ELF data to assess drug exposure. In addition,
all ceftolozane and tazobactam ELF concentrations observed
during the dosing interval remained above target concentrations,
further supporting use of the pooled profile.
In conclusion, in these ventilated, critically ill patients with
pneumonia, 3 g of ceftolozane/tazobactam was generally well
tolerated and yielded ELF exposures sufficient to treat susceptible
Gram-negative lower respiratory tract pathogens with ceftolo-
zane/tazobactam MIC values up to 4 mg/L; these target ELF
exposures were also achieved in patients with moderate/severe
renal impairment and patients with augmented renal clearance.
These data, obtained from a robustly designed clinical trial that
is unique in this therapeutic area, lend additional support to the
clinical use of the 3 g q8h dosing regimen recently approved for
HABP/VABP.20,22–24
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